Jefferies, Piper Sandler and Guggenheim acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics announces common stock offering, no amount given
- Compass Therapeutics price target raised to $12 from $10 at Guggenheim
- Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions
- Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress
- Compass Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating